Stockscreener 앱 받기
13.50
6.32%
-0.91
시간 외 거래:
13.64
0.14
+1.04%
전일 마감가:
$14.41
열려 있는:
$13.84
하루 거래량:
21,263
Relative Volume:
0.22
시가총액:
$14.06M
수익:
-
순이익/손실:
$-1.13M
주가수익비율:
-0.0394
EPS:
-342.9759
순현금흐름:
$-2.63M
1주 성능:
-11.71%
1개월 성능:
-0.95%
6개월 성능:
+100.89%
1년 성능:
-98.42%
1일 변동 폭
$13.50
$14.49
1주일 범위
$13.06
$15.26
52주 변동 폭
$2.88
$2,235.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
13.50 | 15.01M | 0 | -1.13M | -2.63M | -342.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polyrizon Ltd 주식(PLRZ)의 최신 뉴스
Market Trends: Will Polyrizon Ltd stock hit new highs in YEAR2026 Buyback Activity & Stepwise Trade Execution Plans - baoquankhu1.vn
Polyrizon (PLRZ) CTO details initial share and option holdings - Stock Titan
[Form 3] Polyrizon Ltd. Initial Statement of Beneficial Ownership - Stock Titan
Polyrizon (PLRZ) Chief Science Officer reports share and option holdings - Stock Titan
Director Itzhaik Asaf details restricted share holdings at Polyrizon (PLRZ) - Stock Titan
Polyrizon (PLRZ) director discloses initial restricted share holdings - Stock Titan
Polyrizon (PLRZ) director discloses vested and restricted share holdings - Stock Titan
Carmel Liron details Polyrizon (PLRZ) restricted share ownership and vesting - Stock Titan
Polyrizon (PLRZ) CEO Tomer Izraeli details initial share and option holdings - Stock Titan
Polyrizon (PLRZ) CFO details initial share and option holdings - Stock Titan
Oz Adler Net Worth (2026) - GuruFocus
Polyrizon signs CRO agreement for biocompatibility studies - Investing.com South Africa
Polyrizon Taps Global CRO to Run Key Preclinical Safety Studies Ahead of First Clinical Trials - TipRanks
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program - The Manila Times
Polyrizon (PLRZ) signs global CRO pact to advance nasal hydrogel trials - Stock Titan
Nasal allergy startup Polyrizon readies human trials with safety tests - Stock Titan
Eli Zamir reports ≤5% stake in Polyrizon Ltd. (PLRZ) via Schedule 13G - Stock Titan
Polyrizon (PLRZ) Institutional Ownership 2026 - MarketBeat
Polyrizon Announces GMP Manufacturing of Clinical Trial Material with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - marketscreener.com
Polyrizon completes GMP batch for intranasal product trial By Investing.com - Investing.com South Africa
Aug Intraday: Does Polyrizon Ltd have strong fundamentalsRate Hike & AI Optimized Trade Strategies - baoquankhu1.vn
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - Bitget
Polyrizon completes GMP batch for intranasal product trial - Investing.com India
Polyrizon Completes GMP Clinical Material for Planned U.S. Intranasal Study - TipRanks
Polyrizon (Nasdaq: PLRZ) makes GMP CTM for planned U.S. study - Stock Titan
Polyrizon makes GMP batch for planned U.S. nasal allergy, virus trial - Stock Titan
PLRZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Polyrizon (PLRZ) Amendment: L.I.A. Pure Capital Lists ≤5% Ownership - Stock Titan
What catalysts could drive Polyrizon Ltd. stock higher2026 Price Swings & Daily Price Action Insights - Naître et grandir
Polyrizon retains Nasdaq listing following hearings panel - MSN
PLRZ Technical Analysis & Stock Price Forecast - Intellectia AI
Polyrizon Ltd. (PLRZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PLRZ Should I Buy - Intellectia AI
Polyrizon reports nasal deposition study results for naloxone By Investing.com - Investing.com Australia
Polyrizon reports nasal deposition study results for naloxone - Investing.com
Polyrizon Reports Superior Nasal Deposition for Naloxone Formulation in Comparative Study - TipRanks
Polyrizon (Nasdaq: PLRZ) reports enhanced naloxone nasal deposition study - Stock Titan
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product - marketscreener.com
Lab test: Polyrizon nasal naloxone hits target area 94.6% vs 79.6% - Stock Titan
S&P 500 Gains 1%; April Jobs Top Expectations - Intellectia AI
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker - Yahoo Finance
Polyrizon Ltd. announces $4.97 million securities offering - MSN
Polyrizon recives Nasdaq delisting notice - MSN
Is Polyrizon Ltd. stock a value trapJuly 2025 Retail & Weekly High Return Forecasts - mfd.ru
Polyrizon signs MOU to acquire 51% stake in Arrow Aviation By Investing.com - Investing.com South Africa
Polyrizon stock rises on potential acquisition of Arrow Aviation - Investing.com
Will Polyrizon Ltd. stock hit new highs in YEARQuarterly Trade Report & Smart Money Movement Tracker - mfd.ru
How Polyrizon Ltd. stock benefits from tech adoptionWeekly Stock Report & Weekly High Return Opportunities - mfd.ru
Polyrizon stock rises on potential acquisition of Arrow Aviation By Investing.com - Investing.com Canada
Polyrizon intends to secure controlling stake in profitable private jet operator - marketscreener.com
Polyrizon signs MOU to acquire 51% stake in Arrow Aviation - Investing.com
Polyrizon Ltd (PLRZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):